Historically, professional society guidelines have recommended limited genetic testing for hereditary cancer syndromes (HCS) to patients with cancer thought to be at highest risk for carrying pathogenic/likely pathogenic germline variants (PGVs) in a few selected genes.
Reasons for this approach were largely based on the high costs of testing, perceptions that HCS were rare in the general population, and a paucity of clinical utility.
Discussion of the current evidence that challenges these assumptions and supports the implementation of universal HCS testing among patients with solid tumours.
Lynch Syndrome Ireland 